Stopping Ozempic and Similar Drugs Puts Your Heart at Risk Again
Millions of people take GLP-1 medications for diabetes management and weight loss, and the cardiovascular benefits these drugs deliver have been one of their most celebrated advantages. A significant reduction in the risk of heart attacks, strokes, and related complications has made them appealing far beyond their original purpose. But a large new study has delivered a sobering message to anyone considering stopping: those heart benefits do not last, and they disappear faster than they were built up in the first place.
Research published in the journal BMJ Medicine examined the medical records of more than 333,000 patients with type 2 diabetes treated through the Veterans Health Administration. The findings were striking. Heart health risks began creeping back within just six months of stopping GLP-1 medication, and by the time a year and a half had passed, the cardiovascular advantages that patients had spent years accumulating were almost entirely gone.
The lead researcher described the phenomenon as a kind of metabolic whiplash — a reversal that moves at roughly twice the speed of the original benefit. Benefits that took three years to build were undone in approximately eighteen months of going off the drug. The asymmetry is medically significant and practically important for both patients and the insurers who decide whether to keep covering these medications.
What the Numbers Actually Show
The study compared roughly 132,000 patients prescribed GLP-1 medications against more than 201,000 patients on a different class of diabetes drug called sulfonylureas. Among those who took GLP-1 medications continuously for an average of three years, the results were impressive: an approximately 18% lower risk of heart attacks, strokes, or death compared to those on the alternative treatment.
The picture changed dramatically for those who stopped. Compared to patients who remained on the medication, those who discontinued GLP-1 treatment saw heart risk increase by 4% at six months, 14% at the one-year mark, and 22% by the end of the second year off the drug. At that point, the protective effect had effectively been cancelled out entirely.
The GLP-1 medications examined in the study included both newer household names like semaglutide, sold as Ozempic, and tirzepatide, sold as Mounjaro, as well as older drugs in the same class including liraglutide and exenatide. The findings align closely with results from a separate major clinical trial focused specifically on semaglutide and obesity, which had reported a roughly 20% reduction in major cardiovascular events. That earlier trial also surfaced an intriguing finding: patients experienced heart benefits from the medication even in cases where they did not lose significant weight, suggesting the drug acts on the cardiovascular system through mechanisms that extend beyond weight reduction alone.
A Chronic Condition Requires Chronic Treatment
The practical implications of this research extend into insurance policy, prescribing habits, and the financial reality facing millions of patients. Studies have consistently shown that roughly half of all people who begin taking GLP-1 medications stop within the first year. The two most commonly cited reasons are side effects, particularly nausea and fatigue in the early weeks of treatment, and cost. Many patients simply cannot afford to continue.
Insurance coverage policies frequently compound the problem. Some insurers approve GLP-1 medications for weight loss but discontinue coverage once a patient reaches their weight goal, treating the drug as a short-term intervention rather than ongoing treatment. The new research suggests that approach carries real cardiac consequences for patients who are then left without access to a medication their heart had come to rely on.
Physicians involved in the study and its analysis are calling for a reassessment of how these drugs are categorized and covered. The emerging evidence points toward GLP-1 medications being a long-term or even lifelong treatment for patients with cardiovascular risk, not a course of therapy with a defined endpoint. Stopping, as the data now makes clear, is not a neutral decision. It is one that begins reversing hard-won cardiac protection almost immediately, and completes that reversal faster than most patients or their doctors would expect.
